This company has been marked as potentially delisted and may not be actively trading. Novus Therapeutics (NVUS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock NVUS vs. MTNB, AEON, NRBO, NBY, OBSV, CPHI, AEZS, OGEN, SPRB, and GRAYShould you be buying Novus Therapeutics stock or one of its competitors? The main competitors of Novus Therapeutics include Matinas Biopharma (MTNB), AEON Biopharma (AEON), NeuroBo Pharmaceuticals (NRBO), NovaBay Pharmaceuticals (NBY), ObsEva (OBSV), China Pharma (CPHI), Aeterna Zentaris (AEZS), Oragenics (OGEN), Spruce Biosciences (SPRB), and Graybug Vision (GRAY). These companies are all part of the "medical" sector. Novus Therapeutics vs. Its Competitors Matinas Biopharma AEON Biopharma NeuroBo Pharmaceuticals NovaBay Pharmaceuticals ObsEva China Pharma Aeterna Zentaris Oragenics Spruce Biosciences Graybug Vision Matinas Biopharma (NYSEAMERICAN:MTNB) and Novus Therapeutics (NASDAQ:NVUS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends. Do analysts rate MTNB or NVUS? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Matinas Biopharma 0 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Novus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor MTNB or NVUS? In the previous week, Matinas Biopharma had 1 more articles in the media than Novus Therapeutics. MarketBeat recorded 1 mentions for Matinas Biopharma and 0 mentions for Novus Therapeutics. Matinas Biopharma's average media sentiment score of 0.00 equaled Novus Therapeutics'average media sentiment score. Company Overall Sentiment Matinas Biopharma Neutral Novus Therapeutics Neutral Do institutionals and insiders hold more shares of MTNB or NVUS? 11.8% of Matinas Biopharma shares are held by institutional investors. 4.6% of Matinas Biopharma shares are held by insiders. Comparatively, 2.2% of Novus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has preferable earnings & valuation, MTNB or NVUS? Novus Therapeutics has lower revenue, but higher earnings than Matinas Biopharma. Matinas Biopharma is trading at a lower price-to-earnings ratio than Novus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMatinas Biopharma$1.10M8.61-$24.25M-$3.89-0.48Novus TherapeuticsN/AN/A-$16.01M-$21.58-0.13 Which has more risk and volatility, MTNB or NVUS? Matinas Biopharma has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Novus Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500. Is MTNB or NVUS more profitable? Novus Therapeutics' return on equity of -133.49% beat Matinas Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Matinas BiopharmaN/A -210.21% -138.39% Novus Therapeutics N/A -133.49%-30.52% SummaryMatinas Biopharma beats Novus Therapeutics on 6 of the 11 factors compared between the two stocks. Get Novus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NVUS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NVUS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NVUS vs. The Competition Export to ExcelMetricNovus TherapeuticsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.12M$1.03B$6.14B$10.65BDividend YieldN/A4.84%5.66%4.70%P/E Ratio-0.131.2585.8427.65Price / SalesN/A30.97621.60138.35Price / CashN/A17.6438.3262.20Price / Book0.227.3613.066.79Net Income-$16.01M-$7.96M$3.30B$275.88M Novus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NVUSNovus TherapeuticsN/A$2.87+5.1%N/A+4.2%$4.12MN/A-0.137Gap UpHigh Trading VolumeMTNBMatinas BiopharmaN/A$1.90+0.5%N/AN/A$9.67MN/A-0.3930Gap DownAEONAEON Biopharma0.9449 of 5 stars$0.79-1.9%N/A-99.1%$9.25MN/A4.415Analyst ForecastGap UpNRBONeuroBo PharmaceuticalsN/A$0.94-0.1%N/A-60.0%$8.10MN/A0.0010High Trading VolumeNBYNovaBay PharmaceuticalsN/A$1.34+4.7%$0.85-36.6%N/A$8.05M$9.78M-0.0230Positive NewsGap DownOBSVObsEvaN/AN/AN/AN/A$7.94MN/A0.0050CPHIChina PharmaN/A$1.92-1.8%N/A-92.2%$6.25M$4.40M0.00250Gap DownAEZSAeterna ZentarisN/A$3.08+1.3%N/A-16.8%$5.52M$2.37M-0.2120OGENOragenicsN/A$1.33+1.1%N/AN/A$5.47MN/A-0.195Negative NewsGap DownSPRBSpruce Biosciences0.6841 of 5 stars$8.77-2.1%$131.25+1,397.4%+374.3%$4.93M$1.30M-0.1020GRAYGraybug VisionN/A$3.08-0.5%N/A-18.1%$4.83MN/A-1.7827Gap DownHigh Trading Volume Related Companies and Tools Related Companies MTNB Alternatives AEON Alternatives NRBO Alternatives NBY Alternatives OBSV Alternatives CPHI Alternatives AEZS Alternatives OGEN Alternatives SPRB Alternatives GRAY Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NVUS) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
